[go: up one dir, main page]

CL2009001686A1 - Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados. - Google Patents

Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados.

Info

Publication number
CL2009001686A1
CL2009001686A1 CL2009001686A CL2009001686A CL2009001686A1 CL 2009001686 A1 CL2009001686 A1 CL 2009001686A1 CL 2009001686 A CL2009001686 A CL 2009001686A CL 2009001686 A CL2009001686 A CL 2009001686A CL 2009001686 A1 CL2009001686 A1 CL 2009001686A1
Authority
CL
Chile
Prior art keywords
intermediate compounds
compounds considered
agomelatine
preparing agomelatine
preparing
Prior art date
Application number
CL2009001686A
Other languages
English (en)
Inventor
Lecouve Jean-Pierre
Hardouin Christophe
Bragnier Nicolas
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40352219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001686(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CL2009001686A1 publication Critical patent/CL2009001686A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
    • C07C233/91—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated with carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)

Abstract

Procedimiento de preparación de la agomelatina; y el uso decompuestos intermediarios para la síntesis de la agomelatina.
CL2009001686A 2008-08-05 2009-08-03 Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados. CL2009001686A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0804465A FR2934859B1 (fr) 2008-08-05 2008-08-05 Nouveau procede de synthese de l'agomelatine

Publications (1)

Publication Number Publication Date
CL2009001686A1 true CL2009001686A1 (es) 2010-07-19

Family

ID=40352219

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001686A CL2009001686A1 (es) 2008-08-05 2009-08-03 Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados.

Country Status (46)

Country Link
US (2) US8212077B2 (es)
EP (1) EP2151428B1 (es)
JP (1) JP5112400B2 (es)
KR (1) KR101127278B1 (es)
CN (1) CN101643434B (es)
AP (1) AP3167A (es)
AR (1) AR074888A1 (es)
AT (1) ATE548345T1 (es)
AU (1) AU2009203105B2 (es)
BR (1) BRPI0902825A2 (es)
CA (1) CA2674760C (es)
CL (1) CL2009001686A1 (es)
CO (2) CO6120163A1 (es)
CR (2) CR10960A (es)
CU (1) CU23859B1 (es)
CY (1) CY1112829T1 (es)
DK (1) DK2151428T3 (es)
EA (1) EA017848B1 (es)
EC (1) ECSP099560A (es)
ES (1) ES2384021T3 (es)
FR (1) FR2934859B1 (es)
GE (1) GEP20125512B (es)
GT (1) GT200900222A (es)
HN (1) HN2009001436A (es)
HR (1) HRP20120407T1 (es)
IL (1) IL200137A (es)
JO (1) JO2818B1 (es)
MA (1) MA31416B1 (es)
ME (1) ME00928B (es)
MX (1) MX2009008196A (es)
MY (1) MY144936A (es)
NI (1) NI200900153A (es)
NZ (1) NZ578825A (es)
PE (1) PE20100262A1 (es)
PL (1) PL2151428T3 (es)
PT (1) PT2151428E (es)
RS (1) RS52352B (es)
SA (1) SA109300502B1 (es)
SG (1) SG158836A1 (es)
SI (1) SI2151428T1 (es)
SV (1) SV2009003343A (es)
TW (1) TWI398428B (es)
UA (1) UA102220C2 (es)
UY (1) UY32012A (es)
WO (1) WO2010015745A1 (es)
ZA (1) ZA200905335B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
WO2011154140A2 (en) 2010-06-10 2011-12-15 Gador S.A. New process for the preparation of n-[2-(7-methoxy-1-naphthyl)-ethyl]acetamide and new crystalline form
CN102229541A (zh) * 2010-09-17 2011-11-02 福建广生堂药业有限公司 阿戈美拉汀n-[2-(7-甲氧基萘-1-基)乙基]乙酰胺的制备方法
CN102531956B (zh) * 2010-12-21 2014-07-09 浙江九洲药业股份有限公司 用于制备阿戈美拉汀的中间体及相关制备方法
FR2970001B1 (fr) 2011-01-05 2013-01-04 Servier Lab Nouveau procede de synthese de l'agomelatine
EP2562151A1 (en) * 2011-08-25 2013-02-27 Dr. Reddy's Laboratories Ltd. Processes for the preparation of agomelatine and its intermediates
ITMI20121444A1 (it) 2012-08-27 2014-02-28 Procos Spa Processo per la produzione di agomelatine
WO2014072998A1 (en) 2012-11-07 2014-05-15 Cadila Healthcare Limited An improved process for preparation of agomelatine
WO2015076296A1 (ja) * 2013-11-20 2015-05-28 マナック株式会社 含臭素ｎ－フェニルジアクリルイミド誘導体及びその製造方法
FR3014434B1 (fr) * 2013-12-05 2015-12-25 Servier Lab Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine
FR3014437B1 (fr) * 2013-12-05 2016-12-23 Servier Lab Nouveau procede de synthese de l'agomelatine
CN114394906A (zh) * 2022-03-24 2022-04-26 中孚药业股份有限公司 一种阿戈美拉汀中间体的制备方法
CN115872887B (zh) * 2022-12-30 2023-07-07 上海国创医药股份有限公司 一种阿戈美拉汀的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE19825454A1 (de) * 1998-06-06 1999-12-16 Aventis Res & Tech Gmbh & Co Verfahren zur Herstellung von aromatischen Olefinen unter Katalyse von Palladiumkatalysatoren mit Phosphitliganden
FR2784375B1 (fr) * 1998-10-12 2000-11-24 Adir Nouveaux derives cycliques a chaine cycloalkylenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19859684A1 (de) * 1998-12-23 2000-06-29 Bayer Ag Verfahren zur Herstellung von Fluor enthaltenden Phenethylaminen sowie neue, Fluor enthalende beta-Iminovinyl- und beta-Iminoethylbenzole
DE19931116A1 (de) * 1999-07-06 2001-01-11 Bayer Ag Verfahren zur Herstellung von Phenethylaminen und neue chemische Verbindungen
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
CA2556914A1 (en) * 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
RU2006136381A (ru) * 2004-03-15 2008-04-27 Анормед, Инк. (Ca) Способ получения антагониста cxcr4
EP1985620A4 (en) * 2006-02-07 2012-08-15 Taisho Pharmaceutical Co Ltd COMPOUND 10a-AZALIDE
CN101638376B (zh) 2008-07-29 2011-04-27 江苏恩华药业股份有限公司 阿戈美拉汀的制备方法及其中间体

Also Published As

Publication number Publication date
AU2009203105A1 (en) 2010-02-25
JP2010059153A (ja) 2010-03-18
CN101643434B (zh) 2012-07-25
FR2934859A1 (fr) 2010-02-12
HK1141007A1 (en) 2010-10-29
HN2009001436A (es) 2011-09-22
CY1112829T1 (el) 2016-02-10
TWI398428B (zh) 2013-06-11
SI2151428T1 (sl) 2012-06-29
US8212077B2 (en) 2012-07-03
CU23859B1 (es) 2013-02-26
EA200900946A1 (ru) 2010-04-30
UY32012A (es) 2010-01-29
AR074888A1 (es) 2011-02-23
UA102220C2 (ru) 2013-06-25
ATE548345T1 (de) 2012-03-15
PL2151428T3 (pl) 2012-07-31
RS52352B (sr) 2012-12-31
EP2151428B1 (fr) 2012-03-07
US20120245363A1 (en) 2012-09-27
ES2384021T3 (es) 2012-06-28
US20100036162A1 (en) 2010-02-11
AP2009004944A0 (en) 2009-08-31
ME00928B (me) 2012-06-20
HRP20120407T1 (hr) 2012-06-30
CA2674760C (fr) 2012-04-17
GT200900222A (es) 2010-03-15
SG158836A1 (en) 2010-02-26
CN101643434A (zh) 2010-02-10
MA31416B1 (fr) 2010-06-01
ECSP099560A (es) 2010-03-31
CR20150055A (es) 2015-05-18
JP5112400B2 (ja) 2013-01-09
AP3167A (en) 2015-03-31
CO6120163A1 (es) 2010-01-29
MY144936A (en) 2011-11-29
EP2151428A1 (fr) 2010-02-10
GEP20125512B (en) 2012-05-10
FR2934859B1 (fr) 2010-08-13
PT2151428E (pt) 2012-04-18
SV2009003343A (es) 2010-02-01
NI200900153A (es) 2010-03-25
TW201008899A (en) 2010-03-01
KR20100017069A (ko) 2010-02-16
DK2151428T3 (da) 2012-07-02
IL200137A (en) 2013-03-24
IL200137A0 (en) 2010-05-31
CA2674760A1 (fr) 2010-02-05
CO6120150A1 (es) 2010-01-29
NZ578825A (en) 2010-12-24
ZA200905335B (en) 2010-05-26
AU2009203105B2 (en) 2013-09-05
KR101127278B1 (ko) 2012-04-12
EA017848B1 (ru) 2013-03-29
SA109300502B1 (ar) 2013-11-27
MX2009008196A (es) 2010-03-01
PE20100262A1 (es) 2010-04-10
WO2010015745A1 (fr) 2010-02-11
JO2818B1 (en) 2014-09-15
CU20090137A7 (es) 2012-03-15
BRPI0902825A2 (pt) 2011-04-26
CR10960A (es) 2009-09-14

Similar Documents

Publication Publication Date Title
CL2009001686A1 (es) Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados.
CO6410315A2 (es) Nuevos anticuerpos anti-alfa5beta1 y sus usos
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
ECSP10010722A (es) Compuestos orgánicos
ECSP13012519A (es) Compuestos sustituidos de benzamida
CR11623A (es) Compuestos
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
UY32049A (es) Inhibidores de cmet
CR11776A (es) Inhibidores de bace
BRPI0820043A8 (pt) Atividades do receptor de vitamina d e seus usos
CL2008003095A1 (es) Procedeimiento de preparacion de dihidrotienopirimidas; uno de los compuestos intermediarios considerados; y el procedimiento de preparacion de dicho compuesto intermediario.
SV2009003429A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
CL2012000278A1 (es) Proceso para la obtencion de derivados de 5-trifluorometil-pirimidinas; y uno de los compuestos intermediarios considerados.
ECSP088740A (es) Derivados de tetrahidronaftalina, procedimientos para prepararlos y su uso como antiinflamatorios
ECSP13012914A (es) Síntesis de derivados de 2-carboxamida-cicloamino-urea
UY34023A (es) Derivados de fenil-isoxazol y procedimiento para la preparación de los mismos
PA8796801A1 (es) Sintesis quiral de diazepinoquinolinas
UY29434A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como inhibidores de la inflamacinn
BRPI0918664A2 (pt) composição, produto, processo para preparar o composto, e, uso do composto
CL2009001112A1 (es) Compuestos derivados de cinolin-3-carboxamida, inhibidores de la quinasa csf-1r; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CO7071125A2 (es) Composiciones, síntesis y métodos para el uso de derivados de fenilcicloalquilmetilamino